However, other reports suggest that PTHrP can reduce the expression of vascular endothelial growth factor (VEGF) and inhibit tumor angiogenesis in prostate cancer through the activation of protein kinase A (PKA), thereby suppressing tumor growth [4, 36]. The gene discussed is VEGFA; the disease is prostate cancer.